MDHHS is excited to announce the release of the state's Hepatitis C Elimination Plan and launch of the We Treat Hep C Initiative, effective April 1, 2021.
Formal communications regarding the release of the elimination plan and the launch of the We Treat Hep C Initiative were announced in a press release on Thursday, April 1st, 2021. The We Treat Hep C Initiative aims to make curative hepatitis C treatment more accessible by removing barriers to prescribing. Through this initiative, MDHHS has entered into an agreement with AbbVie, the manufacturer of the HCV direct-acting antiviral MAVYRET ®, to make treatment available to all Medicaid and Healthy Michigan Plan beneficiaries. Starting April 1, Michigan Medicaid is removing prior authorization requirements for the preferred HCV medication, MAVYRET®.
The success of the We Treat Hep C Initiative will be directly tied to the state’s clinical community treating patients impacted by HCV. MDHHS is partnering with Wayne State University’s Midwest AIDS Training and Education Center to develop curricula and trainings for interested clinicians. Furthermore, MDHHS is contracting with Henry Ford Health System to maintain an HCV clinical consultation line to provide peer-to-peer advice to clinicians in the process of evaluating and treating their patients for HCV (313-575-0332, Monday – Friday 8 a.m. – 5 p.m., or online).
For more information, updates, and resources, please visit www.Mi.gov/WeTreatHepC or contact the MDHHS Viral Hepatitis Unit at MDHHS-Hepatitis@michigan.gov.